Dashboard
Manage Tickers

INCYINCYTE CORP

Nasdaq incyte.com


$ 51.16 $ -0.56 (-1.08 %)    

Thursday, 25-Apr-2024 15:59:57 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 430.17 $ -2.06 (-0.48 %)
DIA $ 380.88 $ -3.52 (-0.92 %)
SPY $ 507.81 $ -1.92 (-0.38 %)
TLT $ 87.78 $ -0.62 (-0.7 %)
GLD $ 215.92 $ 1.28 (0.6 %)
$ 51.18
$ 51.37
$ 0.00 x 0
$ 0.00 x 0
$ 50.36 - $ 51.78
$ 50.27 - $ 75.74
1,771,923
na
11.56B
$ 0.53
$ 19.35
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-13-2024 12-31-2023 10-K
2 10-31-2023 09-30-2023 10-Q
3 08-01-2023 06-30-2023 10-Q
4 05-02-2023 03-31-2023 10-Q
5 02-07-2023 12-31-2022 10-K
6 11-01-2022 09-30-2022 10-Q
7 08-02-2022 06-30-2022 10-Q
8 05-03-2022 03-31-2022 10-Q
9 02-08-2022 12-31-2021 10-K
10 11-02-2021 09-30-2021 10-Q
11 08-03-2021 06-30-2021 10-Q
12 05-04-2021 03-31-2021 10-Q
13 02-09-2021 12-31-2020 10-K
14 11-05-2020 09-30-2020 10-Q
15 08-04-2020 06-30-2020 10-Q
16 05-05-2020 03-31-2020 10-Q
17 02-13-2020 12-31-2019 10-K
18 10-30-2019 09-30-2019 10-Q
19 07-30-2019 06-30-2019 10-Q
20 04-30-2019 03-31-2019 10-Q
21 02-14-2019 12-31-2018 10-K
22 10-30-2018 09-30-2018 10-Q
23 07-31-2018 06-30-2018 10-Q
24 05-01-2018 03-31-2018 10-Q
25 02-15-2018 12-31-2017 10-K
26 10-31-2017 09-30-2017 10-Q
27 08-01-2017 06-30-2017 10-Q
28 05-04-2017 03-31-2017 10-Q
29 02-14-2017 12-31-2016 10-K
30 11-01-2016 09-30-2016 10-Q
31 08-09-2016 06-30-2016 10-Q
32 05-09-2016 03-31-2016 10-Q
33 02-12-2016 12-31-2015 10-K
34 11-03-2015 09-30-2015 10-Q
35 08-04-2015 06-30-2015 10-Q
36 04-30-2015 03-31-2015 10-Q
37 02-17-2015 12-31-2014 10-K
38 10-30-2014 09-30-2014 10-Q
39 07-31-2014 06-30-2014 10-Q
40 05-01-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

oppenheimer-maintains-outperform-on-incyte-lowers-price-target-to-84
Oppenheimer Maintains Outperform on Incyte...
04/24/2024 11:22:47

Oppenheimer analyst Jay Olson maintains Incyte (NASDAQ:INCY) with a Outperform and lowers the price target from $92 to $84.

incyte-should-consider-significant-stock-buyback-and-prioritize-rd-analyst-recommends
Incyte Should Consider Significant Stock B...
04/23/2024 19:03:10

Incyte acquires Escient Pharmaceuticals for $750 million, bolstering its pipeline. Cantor Fitzgerald initiates coverage with a ...

peeling-back-the-layers-exploring-incyte-through-analyst-insights
Peeling Back The Layers: Exploring Incyte ...
04/23/2024 17:01:13

cantor-fitzgerald-initiates-coverage-on-incyte-with-neutral-rating
Cantor Fitzgerald Initiates Coverage On In...
04/23/2024 12:03:59

Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Incyte (NASDAQ:INCY) with a Neutral rating.

incyte-to-acquire-escient-and-its-assets-for-750m-plus-escients-net-cash-remaining-at-the-close-of-the-transaction-subject-to-customary-adjustments
Incyte To Acquire Escient And Its Assets F...
04/23/2024 11:08:24

Incyte (NASDAQ:INCY) and Escient Pharmaceuticals, a clinical-stage drug discovery and development company advancing novel small...

china-medical-system-announced-collaboration-and-license-agreement-with-incyte-for-selective-oral-smallmolecule-jak1-inhibitor-povorcitinib
China Medical System Announced Collaborati...
04/01/2024 10:40:18

China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that ...

rbc-capital-reiterates-sector-perform-on-incyte-maintains-65-price-target
RBC Capital Reiterates Sector Perform on I...
03/25/2024 14:26:55

RBC Capital analyst Brian Abrahams reiterates Incyte (NASDAQ:INCY) with a Sector Perform and maintains $65 price target.

b-of-a-securities-maintains-neutral-on-incyte-lowers-price-target-to-67
B of A Securities Maintains Neutral on Inc...
03/13/2024 12:04:54

B of A Securities analyst Tazeen Ahmad maintains Incyte (NASDAQ:INCY) with a Neutral and lowers the price target from $69 to...

stifel-reiterates-hold-on-incyte-maintains-68-price-target
Stifel Reiterates Hold on Incyte, Maintain...
03/12/2024 16:33:51

Stifel analyst Stephen Willey reiterates Incyte (NASDAQ:INCY) with a Hold and maintains $68 price target.

incyte-stock-a-deep-dive-into-analyst-perspectives-8-ratings
Incyte Stock: A Deep Dive Into Analyst Per...
03/12/2024 16:00:56

rbc-capital-reiterates-sector-perform-on-incyte-maintains-65-price-target
RBC Capital Reiterates Sector Perform on I...
03/12/2024 15:15:02

RBC Capital analyst Brian Abrahams reiterates Incyte (NASDAQ:INCY) with a Sector Perform and maintains $65 price target.

sunday-incyte-announced-results-from-a-phase-2-study-of-povorcitinib-incb54707-the-study-met-its-primary-endpoint-with-improvement-in-itch-compared-to-placebo-in-prurigo-nodularis
Sunday, Incyte Announced Results From A Ph...
03/11/2024 09:35:59

sunday-incyte-announced-new-results-from-phase-2-study-of-ruxolitinib-cream-opzelura-in-hidradenitis-suppurativa-the-study-met-its-primary-endpoint-demonstrating-significant-reduction-in-abscess-inflammatory-nodule-count-versus-vehicle-control
Sunday, Incyte Announced New Results From ...
03/11/2024 09:34:21

new-data-from-incytes-dermatology-portfolio-to-be-presented-at-the-2024-american-academy-of-dermatology-annual-meeting
New Data From Incyte's Dermatology Portfol...
03/04/2024 13:24:20

Two late-breaking abstracts have been accepted for oral presentation, including randomized studies evaluating ruxolitinib cream...

incyte-announces-fda-grants-priority-review-for-axatilimab-for-chronic-graft-versus-host-disease
Incyte Announces FDA Grants Priority Revie...
02/27/2024 22:44:02

jefferies-initiates-coverage-on-incyte-with-buy-rating-announces-price-target-of-81
Jefferies Initiates Coverage On Incyte wit...
02/23/2024 10:54:32

Jefferies analyst Kelly Shi initiates coverage on Incyte (NASDAQ:INCY) with a Buy rating and announces Price Target of $81.

jmp-securities-downgrades-incyte-to-market-perform
JMP Securities Downgrades Incyte to Market...
02/14/2024 18:13:02

JMP Securities analyst Reni Benjamin downgrades Incyte (NASDAQ:INCY) from Market Outperform to Market Perform.

rbc-capital-maintains-sector-perform-on-incyte-raises-price-target-to-65
RBC Capital Maintains Sector Perform on In...
02/14/2024 15:24:41

RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and raises the price target from $63...

the-analyst-verdict-incyte-in-the-eyes-of-8-experts
The Analyst Verdict: Incyte In The Eyes Of...
02/14/2024 14:00:21

incyte-says-advancing-high-potential-pipeline-provides-opportunity-for-over-10-new-launches-by-2030
Incyte Says Advancing High Potential Pipel...
02/13/2024 12:12:20

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION